RMD
NYSE · USDResMed Inc.
Healthcare · Medical - Instruments & Supplies
CEO Michael J. Farrell
Employees 11,370
R&D / revenue 6.7%
Last price
$238.97−1.35%last session
Market cap
$33.6B
P/E (TTM)
22.9x
From 52w high
−13.9%
From 52w low
+32.6%
1-year return
−11.3%
RSI 14 · vs SMA200
66.5 · +6.3%
IS score
81.9/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)
One year, rebased to 100
RMD SPY XLV (sector ETF) · weekly closesScore DNA
Each bar is a 0-100 score within the scored universe93Profitability
55Growth
63Value
81Momentum
100Risk (safety)
93Quality
91Balance sheet
44Earnings quality
Flags
Strengths
✓ Net cash✓ FCF yield 5%+✓ Congress buying
Warnings
None of the computed warning flags fires for RMD (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Wide, Efficient ScalePiotroski 7 / 9Altman Z 10.0Beta 0.773 of 4 smart-money sources active
Smart-money strip
Each disclosure source on its own window. Filings coinciding is not coordination.INSForm 4 · 180 days
Insider open-market buys
0
8 open-market sales, $8.4M
No Form 144 notices in 12 months
CONGSTOCK Act · 180 days
Congressional purchases
3
Last disclosed purchase 2026-09-11
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−51
94 new holders, 136 closed
892 filers hold 69.9% · 310 added, 363 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+199
1,058 funds adding shares
859 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
75.5%
20-day avg 67.5%, 50-day avg 73.8%
Latest 8.0 pp over its 20-day average · a flow, not short interest
Key financials · FY2026
USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.Income statement
Revenue$5.7B
Revenue growth YoY+9.9%
Gross margin61.1%
Operating income$1.9B
Operating margin33.8%
Net income$1.5B
Net margin26.9%
EPS (diluted)$10.40
Cash flow
Operating cash flow$1.8B
Capital expenditure$156.3M
Free cash flow$1.6B
FCF conversion (FCF / OCF)91.3%
Stock-based compensation$104.3M
FCF less SBC$1.5B
Buybacks$700.0M
Dividends$349.7M
Balance sheet & returns
Cash & short-term investments$1.5B
Total debt$659.4M
Net cash$809.9M
Shareholders' equity$6.6B
Goodwill & intangibles$3.4B
Debt / equity0.13
ROE (TTM)23.9%
ROIC (TTM)19.1%
Operating margin by fiscal year
Revenue $3.6B (FY2022) to $5.7B (FY2026), a 12.1% CAGR.
Valuation
P/E (TTM)22.9x
EV / EBITDA15.2x
Price / sales5.94x
Price / FCF11.6x
FCF yield8.60%
Buyback yield2.08%
SBC / revenue3.2%
Price / book5.25x
Forward P/E FY202719.8x
Forward P/E FY202818.0x
Forward multiples divide today's price by Street EPS estimates. Street mean target $252.43 across 7 analysts last quarter is theirs, not ours.
RMD vs industry median
111 companies in Medical - Instruments & Supplies
RMD (TTM)Industry median
Asset turnover 0.63 vs industry 0.60 · financial leverage 1.36
Earnings delivery
Next report 2026-10-29 · consensus EPS $2.6883%
beat rate, 10 of 12 quarters
+2.1%
median EPS surprise
6
longest beat streak
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-26 to 2026-08-06. Bars cap at ±60%.
Peers
Market-cap band, not the industry cohort above| Company | Mkt cap | P/E | ROE | Net margin | Rev growth | 12m return |
|---|---|---|---|---|---|---|
| RMD ResMed Inc. | $33.6B | 22.9x | 23.9% | 26.9% | +9.9% | −11.3% |
| MDLN Medline Inc. | $31.5B | 41.8x | 3.2% | 0.8% | — | −12.3% |
| WST West Pharmaceutical Services | $27.0B | 48.8x | 19.1% | 17.7% | +12.4% | +43.8% |
| BDX Becton, Dickinson and Compan | $52.2B | 57.8x | 3.8% | 7.6% | −2.6% | +4.0% |
| HOLX Hologic, Inc. | $17.0B | 30.3x | 10.9% | 17.1% | +2.2% | +19.1% |
| SOLV Solventum Corporation | $14.6B | 10.4x | 34.0% | 4.2% | −0.9% | — |
| BAX Baxter International Inc. | $13.1B | n/m | -15.7% | 4.3% | +5.4% | — |
| RGEN Repligen Corporation | $11.1B | 237.1x | 2.0% | 2.5% | +16.5% | — |
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.
Recent 8-K filings
No 8-K filings on file.
Context
Shares outstanding140,639,247
Free float99.1%
Institutional ownership69.9%
Beta0.77
Dividend yield1.03%
Last dividend$0.66 on 2026-08-20
50 / 200-day average$226.66 / $225.05
Large-cap Healthcare median P/E29.7x
Full factsheet
The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Wide).
Read it in the browser Download (PDF)All fundamentals · 140 measures in 13 categories
Percentile = where RMD sits among 26 scored companies in Medical - Instruments & Supplies (0 = lowest value, 100 = highest). It is a position, not a grade.ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)
Valuation
| Measure | RMD | Industry percentile |
|---|---|---|
| P/E (TTM) | 22.1x | 27th |
| PEG (P/E ÷ 3-yr EPS CAGR) | 1.10 | 43rd |
| Price / sales | 5.9x | 79th |
| Price / book | 5.1x | 71st |
| Price / tangible book | 8.8x | 67th |
| Price / free cash flow | 11.6x | 5th |
| Price / operating cash flow | 10.6x | 14th |
| Enterprise value | $33.0B | 88th |
| EV / sales | 5.8x | 79th |
| EV / EBITDA | 15.3x | 30th |
| EV / EBIT | 17.1x | 18th |
| EV / free cash flow | 11.4x | 5th |
| Earnings yield | 4.5% | 84th |
| FCF yield | 8.6% | 96th |
| Operating cash flow yield | 9.4% | 88th |
| Graham number (per share) | $103.63 | 100th |
Profitability (TTM)
| Measure | RMD | Industry percentile |
|---|---|---|
| Gross margin | 61.2% | 76th |
| EBITDA margin | 38.2% | 96th |
| Operating margin | 33.5% | 100th |
| EBIT margin | 34.0% | 100th |
| Net margin | 26.9% | 96th |
| NOPAT margin | 26.6% | 100th |
| FCF margin | 51.1% | 100th |
| Operating cash flow margin | 55.8% | 100th |
| R&D / revenue | 6.7% | 58th |
| SG&A / revenue | 19.7% | 12th |
| Stock comp / revenue | 3.2% | 72nd |
| Effective tax rate | 20.6% | 32nd |
Returns on capital
| Measure | RMD | Industry percentile |
|---|---|---|
| ROE (on average equity) | 24.3% | 96th |
| ROA | 17.8% | 100th |
| ROIC | 25.3% | 92nd |
| ROCE | 25.4% | 96th |
| Return on tangible assets | 22.4% | 100th |
| Cash ROIC (OCF / invested capital) | 53.1% | 100th |
| Gross profitability (GP / assets) | 38.6% | 80th |
| ROIC, 3-yr average | 21.8% | 100th |
| ROIC, 5-yr average | 26.2% | 100th |
| ROE, 5-yr average | 22.5% | 100th |
| Incremental ROIC | 66.0% | 62nd |
Growth
| Measure | RMD | Industry percentile |
|---|---|---|
| Revenue growth (TTM YoY) | 9.9% | 57th |
| Revenue growth (QoQ) | 2.3% | 20th |
| Revenue CAGR, 3 yr | 10.2% | 76th |
| Revenue CAGR, 5 yr | 12.1% | 79th |
| Gross profit CAGR, 3 yr | 13.6% | 81st |
| Operating income CAGR, 3 yr | 18.7% | 64th |
| Net income growth (TTM YoY) | 8.8% | 30th |
| Net income CAGR, 3 yr | 19.3% | 64th |
| EPS growth (TTM YoY) | 10.3% | 30th |
| EPS CAGR, 3 yr | 20.0% | 64th |
| EPS CAGR, 5 yr | 26.5% | 91st |
| FCF growth (TTM YoY) | 74.2% | 82nd |
| FCF CAGR, 3 yr | 72.9% | 100th |
| Operating cash flow CAGR, 3 yr | 65.7% | 88th |
| Book value CAGR, 3 yr | 17.5% | 100th |
| Dividend CAGR, 3 yr | 26.1% | 100th |
| Sustainable growth rate | 14.5% | 79th |
Margin history & stability
| Measure | RMD | Industry percentile |
|---|---|---|
| Gross margin, 3-yr average | 58.9% | 64th |
| Operating margin, 3-yr average | 31.5% | 100th |
| Net margin, 3-yr average | 25.3% | 95th |
| FCF margin, 3-yr average | 36.9% | 100th |
| Revenue stability (0-1) | 1.00 | 100th |
| Earnings stability (0-1) | 0.97 | 100th |
| Margin stability (0-1) | 0.96 | 45th |
Liquidity (latest quarter)
| Measure | RMD | Industry percentile |
|---|---|---|
| Cash & short-term investments | $1.5B | 88th |
| Net cash (− = net debt) | $643.3M | 96th |
| Working capital | $2.9B | 88th |
| Current ratio | 3.10 | 64th |
| Quick ratio | 2.42 | 64th |
| Cash ratio (cash + ST investments / current liabilities) | 1.05 | 56th |
| Defensive interval (days) | 584 days | 76th |
Leverage & solvency (latest quarter)
| Measure | RMD | Industry percentile |
|---|---|---|
| Total debt | $825.9M | 48th |
| Debt / equity | 0.13 | 25th |
| Net debt / equity | −0.10 | 33rd |
| Debt / assets | 9.2% | 24th |
| Debt / capital | 11.1% | 25th |
| Debt / EBITDA | 0.38 | 10th |
| Net debt / EBITDA | −0.30 | 25th |
| Interest coverage (EBIT / interest) | 66.2x | 95th |
| Cash interest coverage | 108.8x | 95th |
| Debt payback (years of OCF) | 0.3 yrs | 5th |
| Liabilities / assets | 26.6% | 20th |
| IS credit model rating | AAA | |
| Implied credit spread (bps) | 50 | 0th |
Efficiency
| Measure | RMD | Industry percentile |
|---|---|---|
| Asset turnover | 0.66 | 72nd |
| Fixed asset turnover | 7.69 | 84th |
| Inventory turnover | 2.3 | 40th |
| Receivables turnover | 5.7 | 32nd |
| Days sales outstanding | 64 days | 68th |
| Days inventory outstanding | 156 days | 60th |
| Days payables outstanding | 49 days | 40th |
| Cash conversion cycle (days) | 171 days | 68th |
| Capex / revenue | 4.7% | 62nd |
| Capex / depreciation | 1.14 | 92nd |
| Operating expense ratio | 28.2% | 21st |
Cash flow & earnings quality
| Measure | RMD | Industry percentile |
|---|---|---|
| Operating cash flow / net income | 2.07 | 60th |
| FCF / net income | 1.90 | 60th |
| FCF / operating cash flow | 91.5% | 90th |
| Capex / operating cash flow | 8.5% | 10th |
| Accruals ratio | -19.1% | 12th |
| Sloan accruals ratio | 2.4% | 80th |
| Earnings quality score (0-1) | 0.75 | 13th |
Scores & forensic checks
| Measure | RMD | Industry percentile |
|---|---|---|
| IS score | 82 | 100th |
| IS profitability | 93 | 100th |
| IS growth | 55 | 43rd |
| IS value | 63 | 92nd |
| IS momentum | 81 | 65th |
| IS risk (safety) | 100 | 72nd |
| IS quality | 93 | 100th |
| IS balance sheet | 91 | 92nd |
| IS earnings quality | 44 | 40th |
| IS cash flow | 99 | 100th |
| Piotroski F-score (0-9) | 7 | 68th |
| Altman Z-score | 10.0 | 88th |
| Beneish M-score | −3.29 | 17th |
| Ohlson O-score | −12.34 | 4th |
| IS credit score | 96 | 96th |
Size (TTM)
| Measure | RMD | Industry percentile |
|---|---|---|
| Market cap | $33.6B | 92nd |
| Revenue | $5.7B | 76th |
| EBITDA | $2.2B | 88th |
| Net income | $1.5B | 96th |
| Free cash flow | $2.9B | 96th |
| Total assets | $9.0B | 68th |
| Shareholders' equity | $6.6B | 84th |
| Employees | 11,370 | 48th |
Insider transactions, last 6 months
Form 4 · most recent 12| Date | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-07 | Farrell Michael J. Director, Chairman and CEO |
Option exercise | 4,991 | $146.34 | $730,383 | 484,794 |
| 2026-10-07 | Farrell Michael J. Director, Chairman and CEO |
Open-market sale | 4,991 | $226.33 | $1.1M | 479,803 |
| 2026-10-07 | Farrell Michael J. Director, Chairman and CEO |
Option exercise | 4,991 | $146.34 | $730,383 | 4,993 |
| 2026-09-08 | Farrell Michael J. Director, Chairman and CEO |
Option exercise | 4,991 | $146.34 | $730,383 | 471,247 |
| 2026-09-08 | Farrell Michael J. Director, Chairman and CEO |
Open-market sale | 4,991 | $222.44 | $1.1M | 466,256 |
| 2026-09-08 | Farrell Michael J. Director, Chairman and CEO |
Option exercise | 4,991 | $146.34 | $730,383 | 9,984 |
| 2026-09-02 | Farrell Peter C Director |
Open-market sale | 970 | $234.73 | $227,688 | 51,803 |
| 2026-08-14 | Bloomer Aaron Chief Financial Officer |
Award / grant | 9,072 | — | — | 9,072 |
| 2026-08-14 | Rider Michael J Global General Counsel |
Award / grant | 3,230 | — | — | 12,718 |
| 2026-08-14 | Farrell Michael J. Director, Chairman and CEO |
Award / grant | 13,547 | — | — | 479,803 |
| 2026-08-14 | Leong Justin Chief Product Officer |
Award / grant | 6,461 | — | — | 35,489 |
| 2026-08-07 | Farrell Michael J. Director, Chairman and CEO |
Option exercise | 4,991 | $146.34 | $730,383 | 471,247 |
Shares acquired vs disposed, by month
acquired disposed · all Form 4 typesBy transaction type, 6 months
| Type | Direction | Filings | Shares | Value |
|---|---|---|---|---|
| Award / grant | Acquired | 4 | 32,310 | — |
| Open-market sale | Disposed | 8 | 38,916 | $8.4M |
| Option exercise | Acquired | 6 | 29,946 | $4.4M |
| Option exercise | Disposed | 6 | 29,946 | $4.4M |
| — | Disposed | 3 | 0 | — |
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.
Form 144 notices
| Filed | Filer | Shares proposed | Est. proceeds |
|---|---|---|---|
| None on file. | |||
A Form 144 is notice of a proposed sale, not a confirmed one.
Congress trades
12 months: House 4 trades (3 purchases) · Senate 1 (1 purchases)| Traded | Member | Chamber | Type | Amount | Disclosed |
|---|---|---|---|---|---|
| 2026-09-11 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-10-09 |
| 2026-05-01 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-06-11 |
| 2026-04-13 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-05-13 |
| 2026-03-27 | Alan Armstrong | Senate | Purchase | $1,001 - $15,000 | 2026-07-21 |
| 2026-01-29 | Ro Khanna | House | Sale | $1,001 - $15,000 | 2026-02-10 |
| 2024-05-03 | Tommy Tuberville | Senate | Sale (Full) | $1,001 - $15,000 | 2024-06-14 |
| 2024-05-03 | Tommy Tuberville | Senate | Sale (Full) | $1,001 - $15,000 | 2024-06-13 |
| 2024-05-03 | Thomas Hawley Tuberville | Senate | Sale (Full) | $1,001 - $15,000 | 2024-06-13 |
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.
Largest 13F holders
Quarter to 2026-06-30, the latest most managers have filed| Manager | Shares | Value | % of shares out |
|---|---|---|---|
| BlackRock, Inc. | 12,317,194 | $2.4B | 8.76% |
| VANGUARD CAPITAL MANAGEMENT LLC | 9,474,129 | $1.8B | 6.74% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,913,661 | $1.5B | 5.63% |
| STATE STREET CORP | 6,680,735 | $1.3B | 4.75% |
| GEODE CAPITAL MANAGEMENT, LLC | 4,352,320 | $845.2M | 3.09% |
| Bank of New York Mellon Corp | 4,174,863 | $813.6M | 2.97% |
| FIRST TRUST ADVISORS LP | 2,278,696 | $444.1M | 1.62% |
| Invesco Ltd. | 2,063,578 | $402.1M | 1.47% |
| MORGAN STANLEY | 1,612,772 | $314.3M | 1.15% |
| NORDEA INVESTMENT MANAGEMENT AB | 1,388,008 | $269.6M | 0.99% |
| DEUTSCHE BANK AG\ | 1,322,313 | $257.7M | 0.94% |
| NORTHERN TRUST CORP | 1,299,858 | $253.3M | 0.92% |
| UBS Group AG | 1,285,728 | $250.6M | 0.91% |
| Swedbank AB | 1,274,897 | $248.5M | 0.91% |
| GOLDMAN SACHS GROUP INC | 1,160,426 | $226.1M | 0.83% |
Institutional ownership by quarter
% of shares held by 13F filers
Number of 13F filers holding
Holder changes by quarter
| Quarter | Holders | Ownership | New | Increased | Reduced | Closed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 892 | 69.9% | 94 | 310 | 363 | 136 |
| 2026-03-31 | 943 | 67.5% | 106 | 364 | 320 | 95 |
| 2025-12-31 | 948 | 67.1% | 115 | 335 | 337 | 99 |
| 2025-09-30 | 950 | 63.5% | 117 | 346 | 325 | 74 |
| 2025-06-30 | 923 | 64.1% | 120 | 356 | 325 | 73 |
| 2025-03-31 | 887 | 65.2% | 108 | 349 | 291 | 80 |
| 2024-12-31 | 872 | 62.6% | 150 | 332 | 267 | 66 |
| 2024-09-30 | 804 | 60.4% | 111 | 325 | 257 | 72 |
| 2024-06-30 | 775 | 59.4% | 117 | 308 | 242 | 53 |
| 2024-03-31 | 721 | 57.6% | 100 | 294 | 217 | 61 |
| 2023-12-31 | 691 | 56.1% | 113 | 248 | 242 | 73 |
| 2023-09-30 | 660 | 60.9% | 61 | 248 | 254 | 121 |
Schedule 13D / 13G filers
| Filed | Form | Filer | % of class | Shares |
|---|---|---|---|---|
| None on file. | ||||
Required above 5% of a class; 13G is the passive form.
ETFs with the largest holding
| ETF | Weight in fund | Holding value |
|---|---|---|
| VITSX | 0.04% | $1.0B |
| VTSAX | 0.04% | $1.0B |
| VSMPX | 0.04% | $1.0B |
| VTI | 0.04% | $1.0B |
| VOO | 0.05% | $837.8M |
| VFIAX | 0.05% | $837.8M |
Share structure
Shares outstanding140,639,247
Float139,315,728
Free float99.1%
Income statement
Fiscal years, USD| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Revenue | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Cost of revenue | $1.6B | $1.9B | $2.0B | $2.1B | $2.2B |
| Gross profit | $2.0B | $2.4B | $2.7B | $3.1B | $3.5B |
| R&D | $253.6M | $287.6M | $307.5M | $331.3M | $378.3M |
| SG&A | $739.4M | $874.0M | $917.1M | $991.0M | $1.1B |
| Operating income | $1.0B | $1.1B | $1.3B | $1.7B | $1.9B |
| EBITDA | $1.2B | $1.4B | $1.5B | $1.9B | $2.2B |
| Pretax income | $960.5M | $1.1B | $1.3B | $1.7B | $1.9B |
| Income tax | $181.0M | $204.1M | $243.8M | $276.8M | $396.1M |
| Net income | $779.4M | $897.6M | $1.0B | $1.4B | $1.5B |
| EPS, diluted | $5.30 | $6.09 | $6.92 | $9.51 | $10.40 |
| Diluted shares | 147.0M | 147.5M | 147.6M | 147.3M | 145.0M |
Balance sheet
| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Cash & short-term investments | $273.7M | $227.9M | $238.4M | $1.2B | $1.5B |
| Receivables | $576.0M | $704.9M | $837.3M | $990.7M | $1.0B |
| Inventory | $743.9M | $998.0M | $822.2M | $927.7M | $945.8M |
| Total current assets | $1.9B | $2.4B | $2.4B | $3.5B | $4.3B |
| PP&E, net | $630.5M | $665.8M | $699.1M | $718.3M | $735.0M |
| Goodwill & intangibles | $2.3B | $3.3B | $3.3B | $3.5B | $3.4B |
| Total assets | $5.1B | $6.8B | $6.9B | $8.2B | $9.0B |
| Accounts payable | $159.2M | $150.8M | $237.7M | $278.2M | $308.9M |
| Total current liabilities | $689.3M | $758.5M | $910.7M | $1.0B | $1.4B |
| Long-term debt | $765.3M | $1.4B | $697.3M | $658.4M | $399.4M |
| Total liabilities | $1.7B | $2.6B | $2.0B | $2.2B | $2.4B |
| Shareholders' equity | $3.4B | $4.1B | $4.9B | $6.0B | $6.6B |
Cash flow statement
Outflows are negative| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Net income | $779.4M | $897.6M | $1.0B | $1.4B | $1.5B |
| Depreciation & amortization | $193.8M | $197.6M | $216.2M | $235.8M | $244.2M |
| Stock-based compensation | $65.3M | $71.1M | $80.2M | $91.7M | $104.3M |
| Change in working capital | −$708.1M | −$462.1M | $44.8M | $16.7M | −$74.2M |
| Operating cash flow | $351.1M | $693.3M | $1.4B | $1.8B | $1.8B |
| Capital expenditure | −$156.0M | −$134.0M | −$114.9M | −$89.9M | −$156.3M |
| Free cash flow | $195.1M | $559.3M | $1.3B | $1.7B | $1.6B |
| Investing cash flow | −$229.9M | −$1.2B | −$269.8M | −$200.0M | −$545.2M |
| Net debt issued / repaid | $122.0M | $665.0M | −$730.0M | −$40.0M | −$10.0M |
| Buybacks | $0 | $0 | −$150.0M | −$300.0M | −$700.0M |
| Dividends paid | −$245.3M | −$258.3M | −$282.3M | −$310.9M | −$349.7M |
Ratio history
Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end| FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|
| Gross margin | 56.6% | 55.8% | 56.2% | 59.4% | 61.2% |
| Operating margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.5% |
| Net margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| FCF margin | 5.5% | 13.2% | 27.5% | 32.2% | 51.1% |
| ROE | 25.0% | 24.0% | 22.7% | 25.9% | 24.3% |
| ROIC | 20.3% | 16.8% | 19.4% | 25.1% | 25.3% |
| ROA | 15.9% | 15.2% | 15.0% | 18.6% | 17.8% |
| Debt / equity | 0.27 | 0.38 | 0.18 | 0.14 | 0.13 |
| Interest coverage | 44.8x | 24.3x | 24.9x | 125.3x | 66.2x |
| Current ratio | 2.80 | 3.12 | 2.59 | 3.44 | 3.10 |
| Revenue growth | +11.9% | +18.0% | +10.9% | +9.8% | +9.9% |
| EPS growth | +63.8% | +14.7% | +13.8% | +37.7% | +10.3% |
| P/E at year end | 38.3x | 35.1x | 27.3x | 27.0x | 18.5x |
| EV / EBITDA at year end | 25.5x | 24.3x | 18.7x | 19.4x | 12.8x |
| FCF yield at year end | 0.65% | 1.78% | 4.62% | 4.39% | 10.23% |
| Dividend payout | 31.5% | 28.8% | 27.7% | 22.2% | 40.2% |
Revenue by segment
| FY2021 | FY2022 | FY2023 | FY2024 | |
|---|---|---|---|---|
| Sleep And Respiratory | $2.8B | $3.2B | $3.7B | $4.1B |
| Software As Service | $373.6M | $400.8M | $498.0M | $584.1M |
Revenue by region · FY2024
U [S]$3.0B · 64%
Global$1.7B · 36%
Street estimates by fiscal year
Next report 2026-10-29 · consensus EPS $2.68 · these are analysts' numbers, not ours| Fiscal year | Revenue (mean) | Revenue range | EPS (mean) | EPS range | Analysts | P/E on mean EPS |
|---|---|---|---|---|---|---|
| 2026 | $5.6B | $5.6B – $5.7B | $11.13 | $11.08 – $11.23 | 8 | 21.5x |
| 2027 | $5.8B | $5.8B – $6.0B | $12.10 | $11.76 – $12.26 | 14 | 19.8x |
| 2028 | $6.2B | $6.0B – $6.5B | $13.30 | $13.11 – $13.65 | 14 | 18.0x |
Reported vs expected, every quarter on file
| Reported | EPS expected | EPS actual | EPS surprise | Revenue expected | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|
| 2026-08-06 | $2.89 | $2.95 | +2.1% | $1.5B | $1.5B | +0.2% |
| 2026-04-30 | $2.80 | $2.86 | +2.1% | $1.4B | $1.4B | +0.8% |
| 2026-01-29 | $2.74 | $2.81 | +2.6% | $1.4B | $1.4B | +1.6% |
| 2025-10-30 | $2.51 | $2.55 | +1.6% | $1.3B | $1.3B | +0.2% |
| 2025-07-31 | $2.55 | $2.55 | 0.0% | $1.3B | $1.3B | 0.0% |
| 2025-04-23 | $2.38 | $2.37 | −0.4% | $1.3B | $1.3B | +0.3% |
| 2025-01-30 | $2.32 | $2.43 | +4.7% | $1.3B | $1.3B | +1.2% |
| 2024-10-24 | $2.04 | $2.20 | +7.8% | $1.2B | $1.2B | +3.3% |
| 2024-08-01 | $2.07 | $2.08 | +0.5% | $1.2B | $1.2B | +0.4% |
| 2024-04-25 | $1.91 | $2.13 | +11.5% | $1.2B | $1.2B | +1.9% |
| 2024-01-24 | $1.81 | $1.88 | +3.9% | $1.1B | $1.2B | +1.5% |
| 2023-10-26 | $1.62 | $1.64 | +1.2% | $1.1B | $963.0M | −12.2% |
| 2023-08-03 | $1.69 | $1.60 | −5.3% | $1.1B | $1.1B | −1.6% |
| 2023-04-27 | $1.59 | $1.68 | +5.7% | $1.1B | $1.1B | −0.8% |
| 2023-01-26 | $1.62 | $1.66 | +2.5% | $996.1M | $1.0B | +3.8% |
| 2022-10-27 | $1.52 | $1.51 | −0.7% | $949.8M | $950.3M | +0.1% |
| 2022-08-11 | $1.45 | $1.49 | +2.8% | $910.6M | $914.7M | +0.5% |
| 2022-04-28 | $1.42 | $1.32 | −7.0% | $904.6M | $864.5M | −4.4% |
| 2022-01-27 | $1.52 | $1.47 | −3.3% | $931.6M | $894.9M | −3.9% |
| 2021-10-28 | $1.36 | $1.51 | +11.0% | $866.3M | $904.0M | +4.3% |
| 2021-08-05 | $1.30 | $1.35 | +3.8% | $876.1M | $876.1M | 0.0% |
| 2021-04-29 | $1.22 | $1.30 | +6.6% | $803.2M | $768.8M | −4.3% |
| 2021-01-28 | $1.27 | $1.41 | +11.0% | $630.1M | $800.0M | +27.0% |
| 2020-10-29 | $1.03 | $1.27 | +23.3% | $535.1M | $751.9M | +40.5% |
Off-exchange (dark pool) volume, weekly
FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)| Week of | Notional | Shares | Trades |
|---|---|---|---|
| 2026-08-31 | $367.9M | 1,578,466 | 59,643 |
| 2026-08-24 | $510.0M | 2,159,550 | 64,683 |
| 2026-08-17 | $425.4M | 1,883,539 | 59,300 |
| 2026-08-10 | $483.1M | 2,164,800 | 64,231 |
| 2026-08-03 | $854.7M | 3,943,365 | 97,696 |
| 2026-07-27 | $406.3M | 1,945,133 | 62,140 |
Short-sale share of off-exchange volume
daily 20-day average| Date | Short share | Short volume | Total volume |
|---|---|---|---|
| 2026-10-15 | 75.5% | 358,505 | 474,985 |
| 2026-10-14 | 62.8% | 215,082 | 342,457 |
| 2026-10-13 | 79.6% | 269,029 | 338,039 |
| 2026-10-12 | 81.2% | 398,747 | 490,837 |
| 2026-10-09 | 68.5% | 241,135 | 352,103 |
| 2026-10-08 | 62.7% | 140,548 | 224,295 |
| 2026-10-07 | 64.3% | 251,720 | 391,248 |
| 2026-10-06 | 73.5% | 228,357 | 310,574 |
| 2026-10-05 | 65.3% | 236,600 | 362,295 |
| 2026-10-02 | 65.9% | 255,868 | 388,377 |
A daily flow measure from FINRA, not short interest.
Seasonality
Average return by calendar month| Month | Avg return | Up years | Years |
|---|---|---|---|
| Jan | +2.0% | 65% | 20 |
| Feb | −0.7% | 50% | 20 |
| Mar | +1.9% | 67% | 21 |
| Apr | +1.4% | 50% | 20 |
| May | +0.4% | 65% | 20 |
| Jun | +2.3% | 60% | 20 |
| Jul | +4.4% | 80% | 20 |
| Aug | +0.5% | 50% | 20 |
| Sep | −1.1% | 35% | 20 |
| Oct | +1.1% | 50% | 20 |
| Nov | +3.2% | 80% | 20 |
| Dec | +1.3% | 65% | 20 |
History, not a forecast.
Indicators
as of 2026-10-16RSI 1466.5
MFI70.0
ADX21.2
Stochastic %K / %D91.4 / 91.9
Williams %R-14.9
CCI163
TSI / signal22.1 / 8.2
Chaikin money flow-0.02
ATR$5.35
Bollinger width11.9%
Volume vs 20-day avg1.11x
SupertrendUp
Moving averages and bands
level (price vs level)SMA 20$226.51 (+5.5%)
SMA 50$226.86 (+5.3%)
SMA 200$224.89 (+6.3%)
EMA 21$229.21 (+4.3%)
EMA 50$224.70 (+6.4%)
EMA 200$225.24 (+6.1%)
Bollinger upper$240.04 (−0.4%)
Bollinger lower$212.98 (+12.2%)
Parabolic SAR$223.55 (+6.9%)
Open the live chart, 110+ indicatorsAbout ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
https://www.resmed.com
Key executives
| Name | Title | Pay | Born |
|---|---|---|---|
| Michael J. Farrell | Chief Executive Officer & Chairman | $3.2M | 1972 |
| Justin Leong | Chief Product Officer | $1.5M | 1977 |
| Brett A. Sandercock | Advisor | $1.3M | 1967 |
| Michael Rider | Chief Legal Officer & Secretary | $915,486 | 1958 |
| Aaron Bloomer | Chief Financial Officer | $823,929 | 1986 |
| Keith Serzen | Senior Advisor to the CEO | $573,468 | 1953 |
| Peter C. Farrell | Founder, Chair Emeritus & Non-Executive Director | $420,863 | 1942 |
| Michael Fliss | Chief Revenue Officer | — | — |
Executive pay, latest proxy
| Executive | Year | Salary | Stock awards | Incentive | Total |
|---|---|---|---|---|---|
| Michael Farrell Chief executive officer | 2016 | $845,000 | $5.5M | $1.1M | $7.5M |
| Rob Douglas President and chief operating officer | 2016 | $694,606 | $1.8M | $682,728 | $5.2M |
| Brett Sandercock Chief financial officer | 2016 | $410,640 | $1.7M | $302,713 | $2.5M |
| Jim Hollingshead President – Americas | 2016 | $454,167 | $1.1M | $360,212 | $2.4M |
| David Pendarvis Chief administrative officer, global general counsel and secretary | 2016 | $507,589 | $1.1M | $374,189 | $2.4M |
Employees
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| 2026-08-20 | $0.66 | 2026-09-24 |
| 2026-05-14 | $0.6 | 2026-06-18 |
| 2026-02-12 | $0.6 | 2026-03-19 |
| 2025-11-13 | $0.6 | 2025-12-18 |
| 2025-08-14 | $0.6 | 2025-09-18 |
| 2025-05-08 | $0.53 | 2025-06-12 |
| 2025-02-13 | $0.53 | 2025-03-20 |
| 2024-11-07 | $0.53 | 2024-12-12 |
Moat model
Wide · Efficient Scale · 2026-06-30Cost advantage82
Intangibles77
Switching costs76
Network effect65
Efficient scale83
Our component scores (0-100) and overall 76.9; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17